Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beam Therapeutics Inc
(NQ:
BEAM
)
26.81
+2.29 (+9.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,421,479
Open
24.87
Bid (Size)
26.40 (1)
Ask (Size)
26.90 (1)
Prev. Close
24.52
Today's Range
24.28 - 26.86
52wk Range
16.95 - 49.50
Shares Outstanding
79,199,501
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
A Closer Look at 5 Analyst Recommendations For Beam Therapeutics
August 22, 2024
Via
Benzinga
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
August 14, 2024
William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1...
Via
Benzinga
Performance
YTD
-2.19%
-2.19%
1 Month
-10.06%
-10.06%
3 Month
+10.24%
+10.24%
6 Month
-21.12%
-21.12%
1 Year
+16.26%
+16.26%
More News
Read More
3 Gene Editing Stocks with Potential to Transform Medicine
August 09, 2024
Via
InvestorPlace
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024
August 06, 2024
Via
InvestorPlace
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
August 06, 2024
From
Beam Therapeutics
Via
GlobeNewswire
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
July 28, 2024
Via
Benzinga
IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday
July 25, 2024
Via
Benzinga
Beam Therapeutics Stock Earns RS Rating Jump To 85
July 24, 2024
Via
Investor's Business Daily
Why Is Conn’s (CONN) Stock Down 36% Today?
July 24, 2024
Via
InvestorPlace
Topics
Bankruptcy
Exposures
Financial
Legal
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40
July 24, 2024
Via
InvestorPlace
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
July 23, 2024
Via
Benzinga
3 Gene Editing Stocks Shaping the Future of Medicine
July 22, 2024
Via
InvestorPlace
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
July 18, 2024
Via
Benzinga
Beam Therapeutics Announces Transition of Chief Financial Officer
July 15, 2024
From
Beam Therapeutics
Via
GlobeNewswire
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
July 09, 2024
Via
InvestorPlace
3 Stocks With the Potential to 10X Your Money
July 09, 2024
Via
InvestorPlace
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
July 04, 2024
Via
InvestorPlace
Exposures
Product Safety
3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030
July 03, 2024
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
June 27, 2024
Via
InvestorPlace
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
June 26, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
June 14, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
May 30, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
May 14, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
May 09, 2024
Via
InvestorPlace
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
May 08, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.